Free Trial
NYSEARCA:XBI

SPDR S&P Biotech ETF (XBI) Price, Holdings, & News

$101.54
+0.56 (+0.55%)
(As of 07/26/2024 ET)
Today's Range
$100.96
$103.08
50-Day Range
$87.48
$101.85
52-Week Range
$63.80
$103.52
Volume
8.28 million shs
Average Volume
10.39 million shs
Market Capitalization
$7.74 billion
Assets Under Management
$7.92 billion
Dividend Yield
0.02%
Net Expense Ratio
0.35%
XBI stock logo

About SPDR S&P Biotech ETF (NYSEARCA:XBI)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

XBI Stock Price History

XBI ETF News Headlines

J.P. Morgan’s DIRE Warning
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
XBI June 7th Options Begin Trading
Some Bubbles Are Starting To Pop
J.P. Morgan’s DIRE Warning
When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."
Novartis Looks To Get Back On Track With Q1 Earnings
See More Headlines
Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Biotech ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:XBI
Inception Date
1/31/2006
Fund Manager
Michael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset Class
Equity
Benchmark
S&P Biotech Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
142

Fund Statistics

Assets Under Management
$7.92 billion
Average Daily Volume
$7.90 million
Discount/Premium
-0.05%

Administrator, Advisor and Custodian

Administrator
SSgA Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
116,690
Put Options
49,606
Call Options
67,084
Short Interest
56,860,000 shs

Miscellaneous

Beta
1.11
Creation Unit
50,000
Creation Fee
$250.00
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

SPDR S&P Biotech ETF Expenses

TypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.56%0.54%0.51%0.51%
Other Expenses0.00%0.33%0.50%0.59%0.54%
Total Expense0.35%0.70%0.70%0.74%0.71%
Fee Waiver0.00%-0.45%-0.54%-0.69%-0.59%
Net Expense0.35%0.61%0.60%0.58%0.58%

SPDR S&P Biotech ETF (XBI) Holdings & Exposure

XBI Sector Exposure

XBI Industry Exposure

Key Executives

  • James E. Ross (Age 52)
    President, Trustee
  • Peter A. Ambrosini (Age 69)
    Chief Compliance Officer
  • Michael P. Riley (Age 44)
    Vice President
  • Gary L. French (Age 64)
    Treasurer
  • John W. Clark (Age 46)
    Assistant Treasurer
  • Matthew W. Flaherty (Age 42)
    Assistant Treasurer
  • Chad C. Hallett (Age 47)
    Assistant Treasurer of Street tracks series trust
  • Mary Moran Zeven (Age 52)
    Secretary
  • Scott M. Zoltowski (Age 44)
    Assistant Secretary
  • Dave Kelly
    Independent Trustee

XBI ETF - Frequently Asked Questions

How have XBI shares performed this year?

SPDR S&P Biotech ETF's stock was trading at $89.29 at the beginning of 2024. Since then, XBI shares have increased by 13.7% and is now trading at $101.54.
View the best growth stocks for 2024 here
.

Who are SPDR S&P Biotech ETF's major shareholders?

Top institutional investors of SPDR S&P Biotech ETF include Raymond James & Associates (0.47%), Raymond James Financial Services Advisors Inc. (0.38%), Howard Capital Management Group LLC (0.32%) and Alpha Cubed Investments LLC (0.30%).

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS) and Micron Technology (MU).

This page (NYSEARCA:XBI) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners